BIO-TECHNE earnings release, May 6, 2026

BIO-TECHNE Corp (TECH) · Form 8-K, Item 2.02 · Filed · SEC filing

​

Bio-Techne Releases Third Quarter Fiscal 2026 Results

​

Minneapolis/May 6, 2026/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2026.

​

Third Quarter FY2026 Highlights

​

● Reported and organic revenue declined 2% to $311.4M, negatively impacted by prior-year GMP fast-track orders and timing of large Commercial Supply shipments

​

● GAAP EPS increased to $0.32 from $0.14; adjusted EPS was $0.53, down from $0.56

​

● Large pharma delivered the sixth consecutive quarter of double-digit growth, offset by a continued lag in spending by emerging biotech; U.S. academic markets stabilized with low-single-digit growth

​

● Growth vectors performed well, with mid-single-digit growth in Proteomic Analysis instruments, mid-teens growth in Spatial Biology, and nearly 50% growth in GMP proteins excluding fast-track customers

​

“The Bio-Techne team delivered solid execution amid a mixed end-market environment,” said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. “Large pharma again led results with the sixth consecutive quarter of double-digit growth, supported by momentum in Asia and stabilizing U.S. academic demand. While biotech funding remains healthy, it has not yet translated into broad-based demand across our portfolio.”

​

Kelderman continued, “We are encouraged by early indicators pointing to a more constructive outlook as funding activity and customer purchasing begin to realign. Our portfolio is organized to support durable, high-value applications across the scientific journey, from biological discovery and translational insight to therapeutic development, manufacturing, and precision diagnostics. Together with our strong operating discipline and financial flexibility, Bio-Techne remains well positioned to deliver attractive long-term value for our stakeholders.”

​

Conference Call

​

Bio-Techne will host an earnings conference call today, May 6, 2026, at 8:00 a.m. CDT. To listen, please dial 1-800-343-4136 or 1-203-518-9843 (for international callers), and reference conference ID TECHQ3. The earnings call can also be accessed via webcast through the following link https://investors.bio-techne.com/ir-calendar.

​

A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512- 2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 11161556. The replay will be available from 11:00 a.m. CDT on Wednesday, May 6, 2026, until 11:00 p.m. CDT on Saturday, June 6, 2026.

​

​

Third Quarter Fiscal 2026

​

Revenue

​

Net sales for the third quarter decreased 2% to $311.4 million. Organic revenue decreased 2% compared to the prior year, with foreign currency exchange having a favorable impact of 2%, and non-recurring prior year revenue from a business held-for-sale having an unfavorable impact of 2%.

​

GAAP Earnings Results

​

GAAP EPS was $0.32 per diluted share versus $0.14 in the same quarter last year. GAAP operating income for the third quarter of fiscal 2026 increased 95% to

$75.5 million compared to $38.7 million in the third quarter of fiscal 2025. GAAP operating margin was 24.2% compared to 12.2% in the third quarter of fiscal 2025. Current quarter GAAP operating margin was favorably impacted by ongoing profitability initiatives, the Exosome Diagnostics divestiture, and a non-recurring arbitration payment in the prior year, partially offset by unfavorable product mix.

​

Non-GAAP Earnings Results

​

Adjusted EPS decreased to $0.53 per diluted share compared to $0.56 in the same quarter last year. Adjusted operating income decreased to $106.5 million in the third quarter of fiscal 2026 compared to $110.3 million in the third quarter of fiscal 2025. Adjusted operating margin was 34.2% for the third quarter of fiscal 2026 compared to 34.9% in the third quarter of fiscal 2025. Adjusted operating margin was unfavorably impacted by volume and product mix, partially offset by ongoing profitability initiatives and the Exosome Diagnostics divestiture.

​

Segment Results

​

Management uses adjusted operating results to monitor and evaluate performance of the Company’s business segments, as highlighted below.

​

Protein Sciences Segment

​

The Company’s Protein Sciences segment is one of the world’s leading suppliers of specialized proteins such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biopharma and academic research communities. Additionally, the segment provides an array of platforms essential in various areas of protein analysis. The

Protein Sciences segment’s third quarter fiscal 2026 net sales were $226.2 million, a decrease of 1% from $227.7 million in the third quarter of fiscal 2025. As of December 31, 2023, a business within the Protein Sciences segment met the criteria as held-for-sale; this held-for-sale business has been excluded from the segment’s operating results for both periods presented. Organic revenue decreased 4% for the third quarter of fiscal 2026, with foreign currency exchange having a favorable impact of 3%. The Protein Sciences segment’s operating margin decreased to 44.2% in the third quarter of fiscal 2026 compared to 45.6% in the third quarter of fiscal 2025. The segment’s operating margin decreased primarily due to unfavorable volume and product mix, partially offset by ongoing profitability initiatives.

​

Diagnostics and Spatial Biology Segment

​

The Company’s Diagnostics and Spatial Biology segment develops and provides spatial biology products, carrier screening and oncology kits. The Diagnostics and Spatial Biology segment also provides blood chemistry and blood gas quality controls, hematology instrument controls, immunoassays and other bulk and custom reagents for the in vitro diagnostic market.... (truncated)rd quarter of fiscal 2025. As of June 30, 2025, a business within the Diagnostics and Spatial Biology segment met the criteria as held-for-sale; this held-for-sale business has been excluded from the segment’s fiscal 2026 operating results. Organic revenue growth was 3% for the third quarter of fiscal 2026, with foreign exchange having a favorable impact of 1%. The held-for-sale business had an unfavorable impact of 8%. The Diagnostics and Spatial Biology segment’s operating margin increased to 12.1% in the third quarter of fiscal 2026 compared to 9.4% in the third quarter of fiscal 2025.

The segment’s operating margin was favorably impacted by the Exosome Diagnostics divestiture and ongoing profitability initiatives, partially offset by unfavorable product mix.

​

​

​

​

​

​

​

​

​

About Bio-Techne

​

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high-quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer-focused brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision-making. Bio-Techne operates in 34 locations worldwide and employs approximately 3,100 people. In fiscal year 2025, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories. For more information on Bio-Techne and its brands, please visit www.bio-techne.com or follow the company on social media at

LinkedIn,

X, or

YouTube.

​

Forward Looking Statements:

​

Financial statements

Income Statement

Quarter Ended — (Unaudited)

Quarter Ended – March 31, – 2026Quarter Ended – March 31, – 2025Nine Months Ended – March 31, – 2026Nine Months Ended – March 31, – 2025
Net sales311,415316,181893,847902,671
Cost of sales103,127101,625306,170311,211
Gross margin208,288214,556587,677591,460
Operating expenses:Selling, general and administrative109,338151,269339,242391,881
Operating expenses:Research and development23,45524,57970,82173,464
Operating expenses:Total operating expenses132,793175,848410,063465,345
Operating expenses:Operating income75,49538,708177,614126,115
Operating expenses:Other income (expense)-4,270-434-7,614-4,793
Operating expenses:Earnings before income taxes71,22538,274170,000121,322
Operating expenses:Income taxes20,17815,68642,75930,244
Operating expenses:Net earnings51,04722,588127,24191,078
Earnings per share:Basic0.330.140.820.58
Earnings per share:Diluted0.320.140.810.57
Weighted average common shares outstanding:Basic156,327157,372155,893158,117
Weighted average common shares outstanding:Diluted157,403158,944156,943160,662

Income Statement

Quarter Ended — (Unaudited)

Quarter Ended – March 31, – 2026Quarter Ended – March 31, – 2025Nine Months Ended – March 31, – 2026Nine Months Ended – March 31, – 2025
Total consolidated net sales311,415316,181893,847902,671
Business held-for-sale(1)5,4394,152
Revenue from recurring operations311,415316,181888,408898,519
Gross margin - GAAP208,288214,556587,677591,460
Gross margin percentage - GAAP66.9%67.965.7%65.5
Identified adjustments:Costs recognized upon sale of acquired inventory$—181$—554
Identified adjustments:Amortization of intangibles9,46511,05728,37733,467
Identified adjustments:Stock-based compensation, inclusive of employer taxes4003781,2521,010
Identified adjustments:Restructuring and restructuring-related costs1,1523644,7567,953
Identified adjustments:Impact of business held-for-sale(1)-2,581-147
Identified adjustments:Adjusted gross margin219,305226,536619,481634,297
Identified adjustments:Adjusted gross margin percentage(2)70.4%71.669.7%70.6

Income Statement

Quarter Ended — (Unaudited)

Quarter Ended – March 31, – 2026Quarter Ended – March 31, – 2025Nine Months Ended – March 31, – 2026Nine Months Ended – March 31, – 2025
Net earnings51,04722,588127,24191,078
Net interest expense (income)1,4209814,6553,031
Depreciation and amortization24,16927,57173,21882,792
Income taxes20,17815,68642,75930,244
EBITDA96,81466,826247,873207,145
Amortization of Wilson Wolf intangible assets2,4902,4917,4697,471
Acquisition related expenses and other1,0425,2906,7899,477
Certain litigation charges82238,9275,37040,606
Stock-based compensation, inclusive of employer taxes10,96811,62937,26237,504
Restructuring and restructuring-related costs2,95271614,20115,027
Investment (gain) loss and other non-operating (income) loss1,6181,314
Recovery of assets held-for-sale-3,655-6,789-3,655
Impact of business held-for-sale(1)2,573479
Adjusted EBITDA116,706122,224316,062314,054

Income Statement

Quarter Ended — (Unaudited)

Quarter Ended – March 31, – 2026Quarter Ended – March 31, – 2025Nine Months Ended – March 31, – 2026Nine Months Ended – March 31, – 2025
Net earnings before taxes - GAAP71,22538,274170,000121,322
Identified adjustments:Amortization of intangibles15,38218,83646,11157,136
Identified adjustments:Amortization of Wilson Wolf intangible assets2,4902,4917,4697,471
Identified adjustments:Acquisition related expenses and other1,0425,2906,7899,477
Identified adjustments:Certain litigation charges82238,9275,37040,606
Identified adjustments:Stock-based compensation, inclusive of employer taxes10,96811,62937,26237,504
Identified adjustments:Restructuring and restructuring-related costs2,95271614,20115,027
Identified adjustments:Investment (gain) loss and other non-operating (income) loss1,6181,314
Identified adjustments:Recovery of assets held-for-sale-3,655-6,789-3,655
Identified adjustments:Impact of business held-for-sale(1)2,573479
Identified adjustments:Net earnings before taxes - Adjusted106,499112,508284,300285,367
Identified adjustments:Non-GAAP tax rate22.3%21.5%22.3%21.5%
Identified adjustments:Non-GAAP tax expense23,74924,19063,39961,385
Identified adjustments:Non-GAAP adjusted net earnings82,75088,318220,901223,982
Identified adjustments:Earnings per share - diluted - Adjusted0.530.561.411.39

Income Statement

Quarter Ended — (Unaudited)

Quarter Ended – March 31, – 2026Quarter Ended – March 31, – 2025Nine Months Ended – March 31, – 2026Nine Months Ended – March 31, – 2025
Protein Sciences segment operating income99,999103,910262,327271,564
Diagnostics and Spatial Biology segment operating income10,3198,42327,62915,940
Segment operating income110,318112,333289,956287,504
Corporate general, selling, and administrative-3,802-2,013-7,273-5,241
Adjusted operating income106,516110,320282,683282,263
Amortization of intangibles-15,382-18,836-46,111-57,136
Acquisition related expenses and other-897-5,159-6,341-9,051

Balance Sheet

(Unaudited)

March 31, – 2026June 30, – 2025
ASSETSCash and equivalents209,819162,186
ASSETSAccounts receivable, net214,562206,876
ASSETSInventories201,175189,446
ASSETSCurrent assets held-for-sale12,332
ASSETSOther current assets62,49437,460
ASSETSTotal current assets688,050608,300
ASSETSProperty and equipment, net232,990245,719
ASSETSRight of use assets68,31673,399
ASSETSGoodwill and intangible assets, net1,296,8741,346,534
ASSETSOther assets264,371283,916
ASSETSTotal assets2,550,6012,557,868
LIABILITIES AND STOCKHOLDERS' EQUITYAccounts payable and accrued expenses95,601116,765
LIABILITIES AND STOCKHOLDERS' EQUITYContract liabilities38,43332,571
LIABILITIES AND STOCKHOLDERS' EQUITYIncome taxes payable2,97110,770
LIABILITIES AND STOCKHOLDERS' EQUITYOperating lease liabilities - current14,18114,098
LIABILITIES AND STOCKHOLDERS' EQUITYOther current liabilities2,0921,645
LIABILITIES AND STOCKHOLDERS' EQUITYTotal current liabilities153,278175,849
LIABILITIES AND STOCKHOLDERS' EQUITYDeferred income taxes14,2106,169
LIABILITIES AND STOCKHOLDERS' EQUITYLong-term debt obligations200,000346,000
LIABILITIES AND STOCKHOLDERS' EQUITYOperating lease liabilities76,14183,960
LIABILITIES AND STOCKHOLDERS' EQUITYOther long-term liabilities21,66827,082
LIABILITIES AND STOCKHOLDERS' EQUITYStockholders' equity2,085,3041,918,808
LIABILITIES AND STOCKHOLDERS' EQUITYTotal liabilities and stockholders' equity2,550,6012,557,868

Cash Flow

Nine Months Ended — (Unaudited)

Nine Months Ended – March 31, – 2026Nine Months Ended – March 31, – 2025
CASH FLOWS FROM OPERATING ACTIVITIESNet earnings127,24191,078
Adjustments to reconcile net earnings to net cash provided by operating activitiesDepreciation and amortization73,21882,792
Adjustments to reconcile net earnings to net cash provided by operating activitiesCosts recognized on sale of acquired inventory554
Adjustments to reconcile net earnings to net cash provided by operating activitiesDeferred income taxes8,045-18,825
Adjustments to reconcile net earnings to net cash provided by operating activitiesStock-based compensation expense36,13536,283
Adjustments to reconcile net earnings to net cash provided by operating activities(Gain) Loss on equity method investment335169
Adjustments to reconcile net earnings to net cash provided by operating activitiesAsset impairment restructuring3,2539,961
Adjustments to reconcile net earnings to net cash provided by operating activitiesRecovery of assets held-for-sale-6,789-3,655
Adjustments to reconcile net earnings to net cash provided by operating activitiesOther operating activities-44,781-9,002
Adjustments to reconcile net earnings to net cash provided by operating activitiesNet cash provided by (used in) operating activities196,657189,355
CASH FLOWS FROM INVESTING ACTIVITIESProceeds from sale of available-for-sale investments1,085
CASH FLOWS FROM INVESTING ACTIVITIESAdditions to property and equipment-20,370-26,116
CASH FLOWS FROM INVESTING ACTIVITIESDistributions from Wilson Wolf4,6202,653
CASH FLOWS FROM INVESTING ACTIVITIESInvestment in Spear Bio-15,000
CASH FLOWS FROM INVESTING ACTIVITIESProceeds from sale of assets held-for-sale4,6171,789
CASH FLOWS FROM INVESTING ACTIVITIESNet cash provided by (used in) investing activities-11,133-35,589
CASH FLOWS FROM FINANCING ACTIVITIESCash dividends-37,432-38,004
CASH FLOWS FROM FINANCING ACTIVITIESProceeds from stock option exercises58,19345,513
CASH FLOWS FROM FINANCING ACTIVITIESLong-term debt activity, net-146,00011,000
CASH FLOWS FROM FINANCING ACTIVITIESRepurchases of common stock-24-175,674
CASH FLOWS FROM FINANCING ACTIVITIESTaxes paid on RSUs and net share settlements-10,643-6,288
CASH FLOWS FROM FINANCING ACTIVITIESNet cash provided by (used in) financing activities-135,906-163,453
CASH FLOWS FROM FINANCING ACTIVITIESEffect of exchange rate changes on cash and cash equivalents-1,985-1,434
CASH FLOWS FROM FINANCING ACTIVITIESNet increase (decrease) in cash and cash equivalents47,633-11,121
CASH FLOWS FROM FINANCING ACTIVITIESCash and cash equivalents at beginning of period162,186151,791
CASH FLOWS FROM FINANCING ACTIVITIESCash and cash equivalents at end of period209,819140,670
Full release

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These statements use words and variations of words, such as “will,” “plan,” “continue,” “believe,” “outlook,” “expect,” and “predict.” These statements are made as of the date of this press release, are based on current expectations of future events, and thus are inherently subject to a number of risks and uncertainties, many of which involve factors or circumstances beyond the Company’s control. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the Company’s expectations and projections. These risks, uncertainties, and other factors include, without limitation: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company’s customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.

​

For additional information concerning these risks, uncertainties, and other factors, see the section titled “Risk Factors” in the Company’s most recent annual report on Form 10-K as filed with the Securities and Exchange Commission. We undertake and we expressly disclaim any obligation to update or revise any forward-looking statements due to new information, changed assumptions, or future events, except as required by law. Investors are cautioned not to place undue reliance on forward-looking statements.

​

Non-GAAP Financial Measures:

​

The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the U.S. (GAAP). This press release contains financial measures that have not been calculated in accordance with GAAP. These non-GAAP measures include:

​

​

These non-GAAP measures should not be considered in isolation or as a substitute for any measure derived in accordance with GAAP and may also be inconsistent with similar measures presented by other companies. Reconciliations of these measures to the applicable most closely comparable GAAP measures, and reasons for the Company’s use of these measures, are presented in the attached pages.

​

David.Clair@bio-techne.com

612-656-4416

​

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · BIO-TECHNE earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.